Upcoming Implementation of FDA-Approved Age Limits for Diabetes GLP-1 Agonists
Date: 03/26/24
Effective April 1, 2024, the Louisiana Medicaid Preferred Drug List (PDL) will be implementing age limitations for certain hypoglycemic GLP-1 medications. This change aligns coverage with the FDA-approved prescribing guidelines for these medications.
Action Required:
Louisiana Medicaid providers are advised to review their current patients receiving these medications. Please identify any patients who may not meet the age requirements once implemented on April 1, 2024.
Current prescribers of these medications for any LHCC members outside of the FDA-approved minimum age limit were mailed a notification letter with patient information ahead of the change to allow for time and notice to get patients switched to an age-appropriate medication.
For these patients, please initiate communication to discuss alternative age-appropriate medications for their long-term diabetes management. A continuity of care period detailed in the letter mailed to your office will be in effect after the change to allow for a smooth transition in medication regimens for your patients already on the medication.
| Medication Name | Minimum Age* |
|---|---|
| Dulaglutide (Trulicity®) | 10 years |
| Exenatide (Bydureon® BCise™) | 10 years |
| Exenatide (Byetta®) | 18 years |
| Liraglutide (Victoza®) | 10 years |
| Semaglutide (Ozempic®, Rybelsus®) | 18 years |
| Tirzepatide (Mounjaro®) | 18 years |
*Minimum Age limit implemented in line with FDA-approved indications for the drug as of 2024.
We appreciate your continued care and dedication to keeping your patients, our members, healthy.